Captopril (hydrochloride) | 198342-23-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Captopril (hydrochloride)
• 英文别名: (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid;hydrochloride
• CAS: 198342-23-3
• 化学式: C9H16ClNO3S
• 分子量: 253.75
• InChiKey: FECNGFPXMFYVNI-HHQFNNIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.05
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  58.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• METHOD OF MAKING AND USING FLUORESCENT-TAGGED NANOPARTICLES AND MICROARRAYS
  申请人：Yan Mingdi

  公开号：US20130252843A1

  公开（公告）日：2013-09-26

  Disclosed embodiments concern differentiating and classifying one or more targets using a perhalophenylazide-derived nanoparticle probe, or multiple such probes. Particular embodiments concern using statistical analysis to produce score plots illustrating the level of differentiation and/or classification. Also disclosed are methods for making perhalophenylazide-derived nanoparticle probes, individually or by using a microarray technique. Particular embodiments concern methods for using the per halophenylazide-derived nanoparticle probes to diagnose, detect, and/or treat a disease. Kits comprising the perhalophenylazide-derived nanoparticle probes are also disclosed.

  公开实施例涉及使用经过卤代苯偶氮苯衍生的纳米颗粒探针或多个这样的探针，区分和分类一个或多个目标。特定实施例涉及使用统计分析来产生得分图，以说明区分和/或分类的水平。还公开了制备经过卤代苯偶氮苯衍生的纳米颗粒探针的方法，可以单独使用或使用微阵列技术。特定实施例涉及使用经过卤代苯偶氮苯衍生的纳米颗粒探针来诊断、检测和/或治疗疾病的方法。还公开了包含经过卤代苯偶氮苯衍生的纳米颗粒探针的试剂盒。
• A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
  申请人：JAGOTEC AG

  公开号：EP0795324A2

  公开（公告）日：1997-09-17

  A description is given of a pharmaceutical form for oral administration consisting of a two- or three-layers tablet, wherein at least one layer can rapidly swell by contact with biological and/or aqueous fluids, said swelling resulting in a considerable increase in the tablet volume. Said phenomenon determines a prolonged residence of the pharmaceutical form at the gastric level and therefore allows a slow release of the active ingredient from said pharmaceutical form to the stomach and/or the first tract of the intestine.

  描述了一种由两层或三层片剂组成的口服药物、 其中至少有一层与生物液和/或水液接触后会迅速膨胀，膨胀会导致片剂体积显著增大。这种现象可以延长药剂在胃中的停留时间，从而使活性成分缓慢地从药剂释放到胃和/或肠道的第一道。
• Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
  申请人：MacGregor, Alexander

  公开号：EP2221047A1

  公开（公告）日：2010-08-25

  The invention can be summarized as follows. The present invention provides a reverse-micellar delivery system for enhanced absorption of an agent of interest across biological membranes such as the gastro-intestinal tract of mammals. The reverse-micelles comprise at least one ionic amphipathic compound, and at least one polar active agent ionizable in aqueous or physiological media. The delivery system facilitates transportation of the agent across the gastro-intestinal tract or other membranes and enhances the in-vivo release and availability of the agent(s) of interest within a fluid environment.

  本发明可概述如下。本发明提供了一种反向胶束给药系统，用于增强生物膜（如哺乳动物的胃肠道）对相关药剂的吸收。反向胶束由至少一种离子两性化合物和至少一种可在水介质或生理介质中电离的极性活性剂组成。递送系统有利于药剂通过胃肠道或其他膜的运输，并提高相关药剂在流体环境中的体内释放和可用性。
• Manufacturing process of formulation having improved content uniformity
  申请人：Shionogi & Co., Ltd.

  公开号：US11135217B2

  公开（公告）日：2021-10-05

  The present invention offers the manufacturing method of the solid formulation wherein the standard deviation of the active ingredient content in the solid formulation becomes 5% or less by mixing the excipients which have a median particle size of 15 or more times, preferably 20 times or more to the median particle size of an active ingredient.

  本发明提供了固体制剂的制造方法，通过混合中值粒径是活性成分中值粒径 15 倍或以上，最好是 20 倍或以上的辅料，使固体制剂中活性成分含量的标准偏差变为 5%或以下。
• Dosage form for delivery of multiple drug forms
  申请人：Edgren E. David

  公开号：US20050260264A1

  公开（公告）日：2005-11-24

  Disclosed are controlled release dosage forms and related methods including: (a) a micronized or liquid base form of a drug; (b) either a pharmaceutically acceptable salt form of the drug or starting materials that are capable of reacting to form a pharmaceutically acceptable salt form of the drug; (c) an upper gastrointestinal system pharmaceutically acceptable salt form releasing structure; and (d) a colonic system base form releasing structure.

  所公开的控释剂型及相关方法包括：(a) 药物的微粉化或液体基质形式；(b) 药物的药学上可接受的盐形式或能够反应形成药物的药学上可接受的盐形式的起始材料；(c) 上消化道系统药学上可接受的盐形式释放结构；(d) 结肠系统基质形式释放结构。